Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-Held Lumiphore Signs Cooperation Agreement with Oncology Company

Abstract:
Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA, a company specializing in radiopharmaceutical therapies to treat cancer patients.

Nanostart-Held Lumiphore Signs Cooperation Agreement with Oncology Company

Frankfurt | Posted on October 31st, 2010

The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta, according to the Company.
The highly targeted form of radiotherapy works by using a new class of radiation-emitting pharmaceuticals, called "alpha-pharmaceuticals". These act through molecular binding to cancer cells, where they can then emit alpha particles in precisely the right location to treat the tumor.

The Company said the agreement provides Algeta with an option to the exclusive rights to incorporate the Lumi4 isophthalamide chelation technology from Lumiphore into these targeted radiopharmaceutical therapeutics for cancer.

The Lumi4 complex functions by binding to a radioactive metal ion, which is the radiation source that emits the alpha particles which in turn destroy the tumor. At the same time, another portion of the complex binds to the pharmaceutical substance which is required to identify the tumor cells.

Under the terms of the agreement, Algeta obtains an exclusive 12-month option to an exclusive license for the use of Lumiphore's Lumi4 chelator technology within the field of therapeutic radiopharmaceuticals. The license will also give Algeta the right to use this technology in companion diagnostics, which are radiopharmaceuticals for determining either the suitability of patients for treatment and/or the effectiveness of treatment. Algeta will pay Lumiphore a fee on signing the option agreement and will make further payments should it exercise the option and take up the license.

"Lumiphore's goal is to bring the benefits of bifunctional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

"Using Lumi4 bifunctional chelates could create a new class of radioimmunotherapeutics," explained Thomas Ramdahl, Chief Technology Officer of Algeta. "By linking thorium-227 to selected tumor targeting antibodies using existing non-proprietary chelates, Algeta has already demonstrated in vivo the potential of its proprietary technology for enhancing the performance of radio-immunotherapies based on existing clinical antibodies. We believe that the new chelators will provide even better results."

####

For more information, please click here

Copyright © Nanostart AG,

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern July 21st, 2018

World's fastest man-made spinning object could help study quantum mechanics July 20th, 2018

Relax, just break it July 20th, 2018

Future electronic components to be printed like newspapers July 20th, 2018

Nanomedicine

Nano-kirigami: 'Paper-cut' provides model for 3D intelligent nanofabrication July 13th, 2018

UMBC researchers develop nanoparticles to reduce internal bleeding caused by blast trauma July 13th, 2018

Researchers identify cost-cutting option in treating nail fungus with nanotechnology: GW researcher Adam Friedman, M.D., studied the potential use of nitric oxide-releasing nanoparticles to improve onychomycosis treatment July 11th, 2018

New sensor technology enables super-sensitive live monitoring of human biomolecules July 3rd, 2018

Announcements

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern July 21st, 2018

World's fastest man-made spinning object could help study quantum mechanics July 20th, 2018

Relax, just break it July 20th, 2018

Future electronic components to be printed like newspapers July 20th, 2018

Nanobiotechnology

UMBC researchers develop nanoparticles to reduce internal bleeding caused by blast trauma July 13th, 2018

Researchers identify cost-cutting option in treating nail fungus with nanotechnology: GW researcher Adam Friedman, M.D., studied the potential use of nitric oxide-releasing nanoparticles to improve onychomycosis treatment July 11th, 2018

New sensor technology enables super-sensitive live monitoring of human biomolecules July 3rd, 2018

Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference July 1st, 2018

Alliances/Trade associations/Partnerships/Distributorships

Leti and Oscaro Partner on Letiís New Low-Power, Low-Cost Transceiver to Track Parcels July 12th, 2018

Leti and Soitec Launch a New Substrate Innovation Center to Develop Engineered Substrate Solutions: Industry-inclusive hub promotes early collaboration and learning from substrate to system level July 11th, 2018

Leti & Partners Launch Pilot Program to Assess New Perception Sensors for Autonomous Vehicles July 5th, 2018

Powering the 21st Century with Integrated Photonics: UCSB-Led Team Selected for Demonstration of a Novel Waveguide Platform Which is Transparent Throughout the MWIR and LWIR Spectral Bands June 19th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project